Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Synta Tumbles on Disappointing Cancer Drug Trial

By Pharmaceutical Processing | June 4, 2013

NEW YORK (AP) — Shares of Synta Pharmaceuticals Corp. lost more than a third of their value Monday after the company reported new details from a clinical trial of its cancer drug ganetespib that disappointed investors.

The trial was designed to study ganetespib as a secondary treatment for adenocarcinoma, a type of non-small cell lung cancer. Synta said patients who were treated with ganetespib and the chemotherapy drug docetaxel had median survival of 9.8 months after treatment, compared to 7.4 months for patients treated with docetaxel alone. The ganetespib patients had median survival of 4.5 months before death or the resumption of disease progression, compared to 3.2 months for the docetaxel group.

The Lexington, Mass., company said the results were stronger if patients who quickly got worse during their initial treatment — which happened before the trial — are excluded. It said those patients had median survival of 10.7 months when treated with ganetespib and 6.4 months when treated with docetaxel alone.

Synta said in October that patients treated with ganetespib had longer overall survival and time-to-disease-progression. Earlier this year the company started enrolling patients in a late-stage trial of ganetespib, and it expects to report results in 2014. That trial includes patients who quickly got worse during their first round of treatment.

Synta has no approved drugs.

Shares of Synta fell $2.51, or 34 percent, to close at $4.87. The stock has traded $4.40 and between $11.88 in the last 52 weeks.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE